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recombinant human granulocyte colony stimulating factor (pegfilgrastim) to reduce 
the risk of FN, the incidence rate of FN was 39.5% in the control group, while it 
was 3.04% in the pegfilgrastim group. Pegteograstim (Neulageg®) was shown to 
be non-inferior compared to pegfilgrastimin the phase three clinical trial, so the 
result was directly applied. The number of patients to whom the result applies was 
estimated as 1,440 patients, which is 8% of the annual average number of breast 
cancer patients in South Korea. The hospitalization costs for FN was estimated by 
an average costs of 18 patients admitted to a Catholic University hospital in 2013, 
which was 15,396,014 (±18,847,475) KRW. Costs for isolated ward, 3rd generation 
antibiotics and G-CSF were included on the hospitalization costs for FN. Weighted 
average costs given by Health Insurance Review & Assessment Service were used for 
micro-costing. Results: When assuming an average incidence rate of 20% for FN, 
FN will occur in 1.72% (25 patients), which is a 8.6% decrease with pegfilgrastim as 
well as with pegteograstim. Therefore, when estimating at the sum of the costs of 
pegfilgrastim, pegteograstim and the average cost of hospitalization, the total cost is 
5,572,986,587 KRW for pegfilgrastim while it is 3,499,386,587 KRW for pegteograstim. 
On the other hand, when pegfilgrastim or pegteograstim are not used, the incidence 
rate of FN is 20% (288 patients), and the average cost of hospitalization after FN 
occurs is 4,434,052,032 KRW. ConClusions: When pegteograstim is reimbursed to 
reduce the incidence of FN during chemotherapies for breast cancer with moderate 
risk of FN, about 1 billion KRW saving is expected from a payer perspective.
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objeCtives: Cancer patients are susceptible to infections, including pneumo-
nia, due to immunosuppressive therapies associated with cancer treatment. This 
study aimed to evaluate the budget impact of pneumonia in patients with previ-
ous diagnosed cancer in the Brazilian Private Health System. Methods: Orizon 
database (N= 18 million lives) was used to identify patients with any type of cancer 
followed by a pneumonia hospitalization between October 2010 and December 2013. 
Pneumonia was identified using code of A40.3, B95.3, G00.1, J13, J15, J15.0, J15.3, J15.4, 
J15.8, J15.9, J18, J18.0, J18.9, J20.2, P23.3. Inpatient and related outpatient costs were 
included. Results: A total of 68,717 patients with a pneumonia hospitalization 
were identified. Of those, 2,769 were diagnosed with cancer (WCa) before the pneu-
monia hospitalization for a total of 3,605 hospitalizations. This translated to a mean 
of 1.30 hospitalization per WCa patient. The group without cancer diagnosis (WoCa), 
65,948 pneumonia patients had a total of 81,583 hospitalizations for a mean of 1.24 
hospitalizations. The average costs per patient are BRL2,863.08 for the WoCa group 
and BRL9,288.07 for the WCa group. When considered the costs per hospitalizations 
the values are BRL2,314.60 and BRL7,134.16 respectively. ConClusions: Although 
the number of pneumonia hospitalization per patient was slightly higher in WCa 
compared with WoCA patients, the cost per patient and cost per hospitalization 
was at least 3 times higher in the WCa compared with WoCA patients. This suggests 
pneumonia has a substantial financial impact in patients with cancer who are in 
the Brazilian Private Health System.
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objeCtives: Several multigene prognostic and predictive tests have recently been 
launched. The 21-gene assay (OncotypeDX®), a validated gene expression profil-
ing test that predicts the likelihood of adjuvant chemotherapy benefit in patients 
with early stage breast cancer, was found to be cost-effective and recommended 
in several guidelines. Its use in clinical practice in France is limited because of 
the absence of reimbursement. This study aims to determine if the utilisation of 
the 21-gene assay in private hospitals would provide good value for money from 
a collective perspective in France and whether hospitals can afford using the test 
under the current payment system. Methods: A multicenter retrospective study 
was conducted to estimate the cost of adjuvant chemotherapy from societal and 
national insurance perspectives. The resulting estimate was used as an input of 
a Markov model to assess the cost-effectiveness of the 21-gene assay from the 
French collective perspective and the economic impact of the test on the revenue 
in private hospital organizations. Results: The cost of adjuvant chemotherapy in 
private hospitals was estimated at € 8,218 per patient from the national insurance 
perspective (€ 10,305 from the societal perspective). The 21-gene assay was found 
cost-effective compared to standard practice and cost-saving with inclusion of pro-
ductivity costs. The absence of reimbursement involves a deficit for private hospitals 
of € 3,200 per patient tested. ConClusions: Providing the 21-gene assay in French 
private hospitals would be cost-effective in the French collective perspective. In the 
absence of reimbursement from primary payers, some private hospitals may cover 
the costs of companion diagnostics to improve their attractiveness, but the test 
will be underused, thus depriving patients from a technology that could improve 
their quality of life and using resources that could be freed up for other patients.
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objeCtives: To analyze cost-effectiveness and assses budget impact of novel BRAF 
inhibitors – vemurafenib and dabrafenib – in patients with MMM. Methods: In the 
absence of head to head data we derived a decision model from indirect comparison 
objeCtives: Cancer patients undergo a wide range of laboratory procedures, from 
simple blood tests to complex molecular diagnostics. In cost-effectiveness analyses, 
costs of laboratory testing are often ignored or estimated inappropriately. We present 
real-world costs of laboratory procedures for non-small cell lung cancer (NSCLC) 
patients, per category of laboratory testing. Methods: In a Dutch academic hospi-
tal, all laboratory tests performed for NSCLC patients between 2009 and 2011, were 
recorded and categorized in clinical chemistry; pathology; microbiology; serology, 
hematology, transfusion; pharmacology; and other or unknown. Number of tests per 
type were multiplied with unit costs per test obtained from The Dutch Healthcare 
Authority. Results: 1,015 patients were included, with a total of 171,632 laboratory 
procedures. 392 different types of tests were performed. Mean cost for laboratory 
testing is EUR1,175 (95%CI 1,066-1,283) per patient. For cost allocation and modeling 
purposes, cost per month with laboratory testing (EUR265,95%CI 247-282) and cost 
per day with laboratory testing (EUR96, 95%CI 91-100) are presented. Costs are mainly 
driven by (molecular) pathology (26%), other (25%, mainly order processing fees) and 
clinical chemistry (24%, due to high test volumes). ConClusions: Costs of laboratory 
procedures for NSCLC patients are substantial. Relatively simple blood tests contrib-
ute significantly to these costs due to high test volumes. Main cost driver however 
is molecular testing by the pathologist, for the use of targeted therapies. In pharma-
coeconomic evaluations, taking laboratory costs into account significantly impacts 
results, especially when testing practices differ between treatment alternatives.
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objeCtives: To estimate the budgetary impact of the introduction of PET-CT for 
staging non-small-cell lung carcinoma (NSCLC) in Brazilian Public Healthcare 
System (SUS). Methods: For estimation of the budgetary impact the work con-
sidered patients diagnosed with NSCLC that would be submitted to the PET-CT for 
tumor staging. It was considered the time horizon of 2013, 2014 and 2015. The num-
ber of procedures in those years was calculated from an estimate of the years 2008-
2012, obtained from SUS. It was assumed that by 2013 the demand for PET grows due 
to its incorporation and, from then on, there would be a tendency to annual decrease 
of 7.5%, the same as in previous years. Cost estimates were obtained from recent 
cost-effectiveness literature. Results: The average cost of the PET-CT procedure 
calculated in 2012 is $1,229.92, the value used for 2013 approximately. The 2014 and 
2015 values were adjusted for inflation at rate of 5% per year, resulting $1,291.40 
and $1,355.97, respectively. The total budget impact for each year was calculated 
by multiplying the number of procedures to be performed by its base value minus 
the savings achieved. The values of $2,072,300.84, $2,030,645.11 and $1,988,842.77, 
for the years 2013, 2014 and 2015, were found respectively. ConClusions: The 
introduction of PET-CT in the staging of NSCLC affects the budget of the Ministry 
of Health in 21.8%, 19.6% and 17.5% in the years 2013, 2014 and 2015, respectively.
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objeCtives: The objective of this study was to estimate the incremental Budget 
Impact (BI) and survival benefit of utilizing eribulin for treatment of Metastatic 
Breast Cancer (MBC) in patients with 2-5 prior chemotherapy regimens includ-
ing anthracycline and taxane. Methods: Epidemiology was derived from 2013 
CancerMPact report and National databases (FOSP and INCA). Treatment of 
Physician’s Choice (TPC) arm included capecitabine, gemcitabine, vinorelbine, 
docetaxel and paclitaxel. TPC market shares, efficacy and Adverse Events (AE) data 
were taken from Phase III clinical trial. Total costs comprised of drug costs, admin-
istration costs, direct medical and AE costs. A micro-costing analysis of resource 
utilization for AE treatments and disease management pre and post progressions 
was performed. Local Brazil tariffs for each costs unit were applied to an Excel-based 
model to compare total costs and survival rates with and without eribulin for MBC 
patients across a 5-year horizon from private payers perspective (assumed to cover 
25% of Brazil population). Results: Applying an MBC prevalence rate, proportion 
of patients with active disease and treated with 3rdline chemotherapies the model 
estimates up to 801 patients treated with eribulin out of 3864 eligible patients over 
5 years. Assuming eribulin market share of 2%, 5%, 9%, 14% and 20% in years 1, 2, 3, 
4 and 5, the BI is R$294K, R$741K, R$1345K, R$2111K and R$3043K (net increase of 
0.12% - 1.21%). The main cost offsets include the displacement of more widely-used 
TPC therapies. Eribulin MBC treatment in Brazil is estimated to yield an incremental 
245 progression free patient years and 408 life years in population covered by private 
insurance. ConClusions: Given the limited number of effective treatment options 
available to patients receiving third line chemotherapy, eribulin represents a much 
needed therapy option for this population. With additional survival benefits eribulin 
represents an effective innovative approach to MBC management.
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objeCtives: To conduct a budget impact analysis on the use of Pegteograstim 
(Neulageg®) to reduce the risk of febrile neutropenia (FN) during chemotherapies 
for breast cancer with moderate risk compared to a standard treatment with anti-
biotics and G-CSF after occurrence of FN. Methods: The efficacy of pegylated 
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and cost savings. Further research is needed to determine the cost-effectiveness 
of ATO+ATRA.
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objeCtives: The aim of this study was to compare the costs of disease management 
based on revised diagnoses after centralized histological reviews for sarcoma, GIST, 
and desmoid tumors with the costs based on diagnoses before reviews. Methods: 
A decision tree was constructed. For both options, the initial pathway was the World 
Health Organization (WHO) Classification of soft tissue and bone tumors. Diagnoses 
were considered concordant only when the final diagnosis was categorized in the 
same manner as the initial finding, as defined by the WHO classification. The deci-
sion tree was evaluated over a time horizon of 12 months. Disease management and 
the probabilities were based on a cohort of patients who had a histological review 
performed within the RRePS (Réseau de Référence en Pathologie des Sarcomes) 
network in 2010. The characteristics of the patient and disease, as well as any rel-
evant guidelines, were used. All of the disease managements were defined by the 
authors of this study. The costs were considered from the French National Health 
Insurance (NHI) perspective and the costs of the histological review were extracted 
from the literature. The costs were assessed for each pathway and expressed in 
Euros 2013. The expected costs were calculated. One-way and probabilistic sensitiv-
ity analyses were performed. Results: A total of 2,425 patients underwent a histo-
logical review. Of these, 341 patients were found to have a discordant diagnosis. Ten 
patients were excluded due to missing data. The costs reached € 8,420 (histological 
review included) when disease management was based on revised diagnoses and 
€ 8,610 when not. ConClusions: In addition to the positive impact of centralized 
histological reviews on the quality of diagnosis for sarcoma, GIST, and desmoid 
tumors, our model demonstrated that histological reviews lower the cost of disease 
management for the French NHI.
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objeCtives: A cost analysis investigating TomoTherapy® (Accuray), Elekta 
Volumetric-modulated Arc Therapy (VMAT®) and Varian RapidArc®was conducted 
in patients with head and neck cancer. Methods: The cost-analysis, funded by 
the National Institute of Cancer (INCa), was performed prospectively based on 
a multicenter study. Cost calculations were strictly based on a micro costing 
approach according to the hospitals’ point of view. Only resources which are likely 
to vary between the strategies being compared were considered. Data on consump-
tion of resources were collected from the treatment planning until the end of the 
last irradiation session. Productivity losses of radiotherapy involved personnel 
related to organisational constraints or absenteeism, costs of administrative per-
sonnel, costs of logistics and general management were not taken into account. 
All costs were given in 2013 euros. Numbers of irradiation sessions were compared 
using Kruskal-Wallis test. Uncertainty was captured by one-way and probabilis-
tic sensitivity analyses using a non-parametric bootstrap method. Results: 174 
patients were enrolled in 16 French centers from February 2010 to February 2012. 
173 economic questionnaires were exploitable. The mean numbers of sessions 
were 34.33 (SD: 2.90) for TomoTherapy® (n= 73) and 34.53 (SD: 2.57) for Varian 
RapidArc® (n= 92, p= 0.603). Eight patients were treated with Elekta Volumetric-
modulated Arc Therapy (VMAT®). For irradiation (all sessions included), the over 
cost of TomoTherapy® (n= 73) reached € 1,109 per patient compared to Varian 
RapidArc® (n= 92). Sensitivity analyses showed that the annual operating time of 
the accelerators played a major role in irradiation costs. ConClusions: This is 
to our knowledge the first study highlighting costs incurred by different Intensity-
Modulated ArcTherapy (IMAT) modalities in this setting. Costs of TomoTherapy® 
appeared more expensive than RapidArc®. The study should be now completed 
by a cost-effectiveness analysis in order to shed further light on which modality 
to focus on.
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objeCtives: Diffuse large B-cell lymphoma (DLBCL) is the most common type of 
non-Hodgkin lymphoma and treatment is usually given with curative intent. Using 
restricted datasets derived from clinical trials, previous studies examining the cost 
of treating this cancer have generally focussed on first-line therapy alone; meaning 
of progression-free survival (PFS) curves for dabrafenib and vemurafenib, from their 
respective clinical trials with dacarbazine as a common comparator. The model 
was applied to the conditions of locally-specific population data and treatment 
costs, including adverse events, of patients with MMM. In the model, individuals 
moved from progression-free state to post-progression state or death and were 
followed for 45 weeks. We compared vemurafenib and dabrafenib from the payers’ 
perspective at the price level determined by international reference pricing as of 
December 2013 in terms of costs and progression-free life years (PFLYs). Based on 
the cost-effectiveness model, we carried out budget impact analysis for a scenario 
with vemurafenib only and a scenario with vemurafenib and dabrafenib using their 
projected market shares. Results: Our model has shown that more than 99% of 
total treatment costs of MMM patients in Slovenia were due to drug costs of BRAF 
inhibitors in spite of the fact that treatment of associated adverse events were 5 
times higher in vemurafenib than in dabrafenib, primarily due to higher incidence 
of cutaneous squamous cell carcinoma and keratocanthoma. Treatment with dab-
rafenib vs. vemurafenib allowed to save € 13,009 and gain 0.022 PFLY at a discount 
rate of 3.5%; the sensitivity analysis showed robustness of findings and retained 
dominance of dabrafenib over vemurafenib. Budget impact analysis for a 3-year 
period revealed that introduction of dabrafenib would save the national Sick Fund 
€ 402,000 (€ 5,318,000 in the scenario without dabrafenib vs. € 4,916,000 in the sce-
nario with dabrafenib). ConClusions: Study results suggest that introduction of 
dabrafenib in Slovenia could reduce costs and improve outcomes in MMM.
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objeCtives: Multidisciplinary return-to-work (RTW) interventions effectively sup-
port cancer survivors to resume work and potentially increase quality of life, but 
are not or only partly reimbursed by health insurers. To ensure optimal support for 
cancer patients in resuming work, it is essential that hospitals can offer RTW in a 
financially viable way. We analysed the budget impact of a RTW intervention (coun-
selling by occupational physicians + physical exercise) and explored how financing 
of a return-to-work intervention can be arranged. Methods: The budget impact 
analysis compared costs of RTW support for all patients able and willing to resume 
work versus no standardised support, for a large cancer centre serving a popula-
tion of 1 million inhabitants. Costs and financial benefits relevant from a societal 
perspective were considered, including intervention costs, productivity losses, and 
patients´ costs. We identified which stakeholders, including hospitals, employers, 
health insurances, social security, and patients accrue what costs; and which enjoy 
the financial benefits under different financing arrangements. Results: RTW costs 
are ≈ € 2,000 per patient. For a large cancer centre, the annual budget impact is € 817k 
in 2014, rising to € 14.7m in 2017. Ccosts for patients with a multidisciplinary rehabil-
itation need are typically covered by health insurance, leaving € 735k to be financed 
by the cancer centre. Small improvements in return-to-work and quality of life led 
to substantial reductions in productivity loss and future health care costs. These 
savings outweigh the costs of the intervention, rendering RTW cost-saving from a 
societal perspective. ConClusions: From a societal perspective return-to-work is 
expected to be cost-saving. Hospitals bear the largest share of the cost, while most 
financial benefits fall upon other stakeholders. Re-distributing costs and financial 
benefits among stakeholders would result in feasible financing of the intervention.
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objeCtives: To estimate the total costs of arsenic trioxide and all-trans retinoic 
acid (ATO+ATRA) versus ATRA and idarubicin (AIDA) regimens in Italy when used 
in 1st-line APL treatment. ATO+ATRA is approved in 2st-line treatment, but com-
monly used globally in 1st-line. Methods: A Markov model was developed with 
three health states: non-progressive disease, progressive disease and death. Each 
month, patients could move from non-progressive to progressive disease or die 
from either state. After progression, patients discontinued treatment and switched 
to the other regimen. Treatment regimens, efficacy and adverse events were derived 
from published sources and expert opinion, while each arm’s unit costs (induc-
tion and consolidation for both; maintenance for AIDA only) were collected from 
standard Italian sources. Per-patient costs were reported, and extensive one-way 
sensitivity analyses were conducted. Results: Expected 2-year pharmacy costs 
for ATO+ATRA were € 46,600 versus € 5,300 for AIDA. However, direct medical (DM) 
costs (e.g., monitoring, hospitalizations, etc.) for ATO+ATRA were € 11,300 versus 
€ 28,500 for AIDA. The higher costs stemmed from AIDA consolidation taking place in 
a hospital setting and 2-year maintenance monitoring costs. The treatment failure 
likelihood for patients on AIDA was 14% versus 3% on ATO+ATRA. As these patients 
switched to 2nd-line treatment, relapse costs for AIDA were € 1,500 compared to € 400 
for ATO+ATRA. AIDA patients incurred higher costs from adverse events (AEs) than 
ATO+ATRA (€ 600 vs. € 300, respectively). Results were most sensitive to consolida-
tion cost changes: ATO+ATRA pharmacy costs and AIDA DM costs. ConClusions: 
The results suggest potential cost savings due to DM, progression and AE costs 
for ATO+ATRA, although AIDA pharmacy costs are lower. Additionally, ATO+ATRA 
patients have lower clinical AE risks and shorter treatment duration (8 months 
versus 28 months for AIDA), which could lead to patients’ improved quality of life 
